The global market for Mumps Vaccines was estimated at US$650.5 Million in 2024 and is projected to reach US$993.5 Million by 2030, growing at a CAGR of 7.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Mumps Vaccines market.
Routine immunization programs in many countries include the mumps vaccine as a two-dose schedule during early childhood, often reinforced with booster doses in adolescence or adulthood in outbreak-prone regions. Because of its role in broader viral containment strategies, the mumps vaccine is not only critical for individual protection but also essential for maintaining community-level herd immunity particularly in schools, universities, military installations, and other high-density environments.
Some public health authorities are also exploring the development of monovalent or bivalent boosters to augment mumps-specific immunity, especially in populations experiencing waning antibody levels. Efforts to develop thermostable formulations and intranasal delivery systems are under way to improve vaccine uptake in low-resource settings. Moreover, genomic surveillance is being used to monitor circulating mumps strains and assess vaccine-strain match, helping update recommendations and refine immunization schedules.
Populations in conflict zones or regions with disrupted healthcare infrastructure are also priority targets for mumps vaccination through international aid and mass immunization campaigns. Seasonal and travel-based vaccination spikes are seen in countries that experience migratory influxes or host large international events. As awareness of vaccine-preventable diseases improves and global immunization funding increases, both public and private healthcare systems are intensifying their focus on mumps control.
Global Mumps Vaccines Market - Key Trends & Drivers Summarized
Why Are Mumps Vaccines Critical to Global Public Health Strategies?
Mumps vaccines play a pivotal role in preventing outbreaks of mumps, a contagious viral disease characterized by swelling of the salivary glands, fever, headache, and in some cases, complications such as meningitis, orchitis, and hearing loss. The vaccine commonly administered as part of the MMR (measles, mumps, and rubella) combination has significantly reduced global mumps incidence since its introduction. However, recent outbreaks, even in highly vaccinated populations, have reignited the focus on improving coverage and long-term immunity.Routine immunization programs in many countries include the mumps vaccine as a two-dose schedule during early childhood, often reinforced with booster doses in adolescence or adulthood in outbreak-prone regions. Because of its role in broader viral containment strategies, the mumps vaccine is not only critical for individual protection but also essential for maintaining community-level herd immunity particularly in schools, universities, military installations, and other high-density environments.
How Are Vaccine Technologies Evolving to Address Efficacy and Coverage Challenges?
Most mumps vaccines in use today are live attenuated virus formulations, primarily derived from strains such as Jeryl Lynn, Leningrad-Zagreb, or Urabe. While effective, these strains exhibit varying immunogenicity and duration of protection, which can influence long-term effectiveness and population-level outbreak resilience. As a result, research is ongoing into improving vaccine efficacy through new attenuation techniques, strain modification, and enhanced adjuvant systems.Some public health authorities are also exploring the development of monovalent or bivalent boosters to augment mumps-specific immunity, especially in populations experiencing waning antibody levels. Efforts to develop thermostable formulations and intranasal delivery systems are under way to improve vaccine uptake in low-resource settings. Moreover, genomic surveillance is being used to monitor circulating mumps strains and assess vaccine-strain match, helping update recommendations and refine immunization schedules.
Which Regions and Demographic Groups Are Driving Market Demand?
High-income countries with established immunization programs continue to drive demand for MMR vaccines, particularly through pediatric schedules and school-entry requirements. However, adult booster programs are expanding in response to mumps outbreaks in universities and healthcare settings. In emerging economies, efforts to scale up routine immunization coverage are boosting primary demand for the MMR vaccine, including in parts of South Asia, Sub-Saharan Africa, and Latin America.Populations in conflict zones or regions with disrupted healthcare infrastructure are also priority targets for mumps vaccination through international aid and mass immunization campaigns. Seasonal and travel-based vaccination spikes are seen in countries that experience migratory influxes or host large international events. As awareness of vaccine-preventable diseases improves and global immunization funding increases, both public and private healthcare systems are intensifying their focus on mumps control.
The Growth in the Mumps Vaccines Market Is Driven by Several Factors…
The growth in the mumps vaccines market is driven by several factors including increasing global immunization efforts, resurgence of mumps outbreaks in highly populated areas, and expanded awareness of complications associated with the disease. Technological advances in vaccine formulation, cold chain logistics, and strain optimization are improving both efficacy and accessibility. Rising investments in pediatric and adolescent health, enhanced surveillance infrastructure, and updated national immunization guidelines are also supporting demand. As healthcare systems prioritize infectious disease preparedness and universal vaccine coverage, the mumps vaccine market is set for sustained growth across both developed and developing economies.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Monovalent segment, which is expected to reach US$483.5 Million by 2030 with a CAGR of a 9.0%. The Combinational segment is also set to grow at 4.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $177.2 Million in 2024, and China, forecasted to grow at an impressive 11.7% CAGR to reach $212.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Mumps Vaccines Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Mumps Vaccines Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Mumps Vaccines Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Bharat Biotech, Bio Farma, China Bio-Immunity Corporation, GlaxoSmithKline plc (GSK), and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Mumps Vaccines market report include:
- Bharat Biotech
- Bio Farma
- China Bio-Immunity Corporation
- GlaxoSmithKline plc (GSK)
- Haffkine Bio-Pharmaceutical Corp.
- Indian Immunologicals Ltd.
- Instituto Butantan
- Kitasato Daiichi Sankyo Vaccine Co., Ltd.
- LG Chem
- Merck & Co., Inc.
- Microgen
- Panacea Biotec Ltd.
- Sanofi Pasteur
- Serum Institute of India Pvt. Ltd.
- Shanghai Institute of Biological Products
- Sinovac Biotech Ltd.
- Takeda Pharmaceutical Company Ltd.
- The Research Institute for Biological Safety Problems
- Torii Pharmaceutical Co., Ltd.
- Zydus Lifesciences Ltd.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bharat Biotech
- Bio Farma
- China Bio-Immunity Corporation
- GlaxoSmithKline plc (GSK)
- Haffkine Bio-Pharmaceutical Corp.
- Indian Immunologicals Ltd.
- Instituto Butantan
- Kitasato Daiichi Sankyo Vaccine Co., Ltd.
- LG Chem
- Merck & Co., Inc.
- Microgen
- Panacea Biotec Ltd.
- Sanofi Pasteur
- Serum Institute of India Pvt. Ltd.
- Shanghai Institute of Biological Products
- Sinovac Biotech Ltd.
- Takeda Pharmaceutical Company Ltd.
- The Research Institute for Biological Safety Problems
- Torii Pharmaceutical Co., Ltd.
- Zydus Lifesciences Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 288 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 650.5 Million |
| Forecasted Market Value ( USD | $ 993.5 Million |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
